Last updated: 2026-09-16 11:44:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
CytoMed Therapeutics Limited (GDTC) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $0.82, with a market capitalisation of $10.08M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.68 to $3.68. This page covers its latest market performance, valuation, price trends and company information.
$10.08M | |
$0.90 | |
$9.25 | |
$0.68 | |
$0.85 | |
19.74K | |
79.24K | |
-- | |
$3.68 | |
$0.68 | |
-- | |
-- |
CytoMed Therapeutics Limited (GDTC) is trading at $0.87 in pre-market trading as of 2026-09-15 23:35:00, up 2.27% ($0.02) from the previous close of $0.85
Pre-market trading shows how investors are pricing GDTC before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, CytoMed Therapeutics Limited (GDTC) moved from $0.86 to $0.82, representing a decline of 4.31% ($0.04).
The stock traded between $0.77 and $0.93 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 13.82 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 4.8%
GDTC is currently trading at $0.82, placing it 4.8% of the way from its 52-week low of $0.68 to its 52-week high of $3.68. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
| Employees | 42 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of CytoMed Therapeutics Limited (GDTC) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.